We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
EffRx Pharmaceuticals SA announced it has recently entered into an exclusive license agreement with Diurnal Group plc for the registration and commercialization of Alkindi for pediatric adrenocortical insufficiency (AI) in Switzerland.